FDA Tentatively OKs Merck Biosimilar To Sanofi Diabetes Drug
The U.S. Food and Drug Administration has tentatively approved Merck & Co. Inc.'s biosimilar to Sanofi's diabetes treatment Lantus, though the decision will remain paused while Sanofi's patent infringement lawsuit is...To view the full article, register now.
Already a subscriber? Click here to view full article